Evidence map›Paper›PMID 25788875›Full record

ReviewFrontiers in neuroscience2015

Understanding the rules of the road: proteomic approaches to interrogate the blood brain barrier.

Bruce E Torbett, Andrew Baird, Brian P Eliceiri

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. The Translational Significance of the Neurovascular Unit.The Journal of biological chemistry · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Bruce E TorbettMolecular and Experimental Medicine, The Scripps Research Institute La Jolla, CA, USA.
Andrew BairdDepartment of Surgery, University of California, San Diego San Diego, CA, USA.
Brian P EliceiriDepartment of Surgery, University of California, San Diego San Diego, CA, USA.
University of California, San Diego · USScripps Research Institute · US

Funding

A Combinatorial Approach to Wound Healing for Protein, Gene and Cell TherapeuticsP20GM078421 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAIRD, ANDREW · 2006 to 2009
$3.4M
Vascular mechanisms regulating breast cancer brain metastasisR01CA170140 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELICEIRI, BRIAN P, FELDING, BRUNIE H. · 2012 to 2016
$1.8M
Targeting the choroid plexus for drug translocation into CSFR21EY018479 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAIRD, ANDREW · 2007 to 2010
$606k
NCI NIH HHS R01 CA170140NEI NIH HHS R21 EY018479NIGMS NIH HHS P20 GM078421
6 · The paper itself

Abstract

The blood brain barrier (BBB) is often regarded as a passive barrier that protects brain parenchyma from toxic substances, circulating leukocytes, while allowing the passage of selected molecules. Recently, a combination of molecular profiling techniques have characterized the constituents of the BBB based on in vitro models using isolated endothelial cells and ex vivo models analyzing isolated blood vessels. Characterization of gene expression profiles that are specific to the endothelium of brain blood vessels, and the identification of proteins, cells and multi-cellular structure that comprise the BBB have led to a emerging consensus that the BBB is not, in and of itself, a simple barrier of specialized endothelial cells. Instead, regulation of transcytosis, permeability, and drug translocation into the central nervous system is now viewed as a collection of neurovascular units (NVUs) that, together, give the BBB its unique biological properties. We will review recent technology advancing the understanding of the molecular basis of the BBB with a focus on proteomic approaches.

Indexed as

blood brain barriermass spectrometryproteomicsvascular diseases

Identifiers

PMID25788875
PMCPMC4349081
OpenAlexW2083860491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.